Colorectal cancer

Colorectal cancer

It has recently been discovered that the formation, growth and spread of tumors in colorectal cancer is promoted by certain bacteria in the large intestine, including fusobacteria, toxin-producing enterococci, coliforms and Bacteroides spp. These can occur in biofilm that invades the colon’s superficial mucus layer, and some can also infect the tumors, and promote growth and resistance to radio and chemotherapy.

Reponex has designed a pharmaceutical preparation to, in a new way, eradicate or reduce these carcinogenic bacteria in the colon and eliminate the bacterial biofilm by intraintestinal administration of high concentrations of fosfomycin in combination with metronidazole. A clinical Phase IIa proof-of-concept study on colorectal cancer and colon adenomas is underway at Zealand University Hospital.